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ABSTRACT	
Benzydamine	 (BZY)	 is	 a	non-steroidal	 anti-inflammatory	drug	 (NSAID)	used	 for	 the	 topical	
treatment	 of	 inflammations	 of	 the	 oral	 and	 vaginal	 mucosa.	 	 Virtually	 nothing	 is	 known	
about	 the	 central	 pharmacological	 actions	 of	 BZY.	 	 Yet,	 there	 are	 reports	 of	 voluntary	
systemic	overdosage	of	BZY	in	drug	addicts,	resulting	in	a	euphoric,	hallucinatory	state.	 	 In	
the	 present	 study,	 we	 investigated	 the	 reinforcing	 properties	 of	 BZY	 in	 a	 rat	 self-
administration	paradigm.		We	found	that	BZY	has	a	powerful	reinforcing	effect	and	that	this	
effect	 is	 greatly	 facilitated	 in	 animals	 that	 already	 had	 substance	 experience,	 having	
previously	self-administered	heroin	and	cocaine,	indicating	cross	sensitization	between	BZY	
and	other	common	drugs	of	abuse.		We	then	assessed	the	effect	of	BZY	on	Prelimbic	Cortex-
to-Nucleus	Accumbens	(PLCx-NAcc)	glutamatergic	transmission,	using	field	recordings	in	rat	
parasagittal	brain	slices.		BZY	dose-dependently	reduced	both	field	excitatory	post	synaptic	
potential	 (fEPSP)	 amplitude	 and	 Paired	 Pulse	 Ratio	 (PPR),	 suggesting	 a	 presynaptic	
mechanism	of	action.		Similarly	to	the	in	vivo	paradigm,	also	the	electrophysiological	effects	
of	BZY	were	potentiated	in	slices	from	animals	that	had	undergone	cocaine	and	heroin	self-
administration.	 	 Furthermore,	 BZY-induced	 LTD-like	 responses	 in	 the	 PLCx-NAcc	 circuitry	
were	 significantly	 reduced	 in	 the	presence	of	 the	CB1	 receptor	antagonist	AM251.	 	These	
findings	 provide	 firm	 evidence	 of	 the	 abuse	 liability	 of	 BZY	 and	 suggest	 a	 possible	
cannabinoidergic	mechanism	of	action.		Further	research	is	needed	in	order	to	give	insights	
into	 the	 molecular	 mechanism	 underlying	 BZY	 psychoactive	 and	 reinforcing	 effects,	 to	
better	understand	its	abuse	potential.	
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INTRODUCTION	
Benzydamine	 (BZY)	 is	 a	 non-steroidal	 anti-inflammatory	 drug	 that	 was	 synthetized	 by	
Angelini’s	 laboratories	 in	 1964	 and	 made	 commercially	 available	 since	 1966	 for	 the	
symptomatic	 treatment	of	 acute	 inflammatory	 states	of	 the	oral	 and	vaginal	mucosae.	 	A	
number	of	pharmaceuticals	preparations	for	topical	use	are	available	(e.g.,	TANTUM®	Verde	
and	GineTANTUM®	 in	 Italy,	 Difflam®	 in	 the	UK,	 Tanflex®	 and	 Benzidan®	 in	 Turkey,	 Flogo-
Rosa®	 in	 Brazil).	 	 Benzydamine	 is	 also	 contained	 in	 medications	 for	 systemic	 use	 (with	
concentrations	 of	 BZY	 ten	 times	 lower	 than	 those	 for	 topical	 use),	 as	 in	 the	 case	 of	
Benflogin®	in	Brazil,	which,	however,	is	no	longer	available	on	the	market.	
The	mechanisms	of	action	of	BZY	are	complex.		The	anti-inflammatory	effect	mainly	
depends	on	the	inhibition	of	prostaglandin	synthesis,	probably	due	to	disruption	of	calcium	
mobilization/sequestration	at	the	level	the	plasma	membrane	of	inflammatory	cells	(Jeremy	
et	 al.,	 1991).	 	 Benzydamine	 also	 exhibits	 a	 less	 specific	 mechanism	 of	 action	 termed	
‘membrane	 stabilization’,	 resulting	 in	 the	 inhibition	of	 granule	 release	by	 neutrophils	 and	
lysosomes	(Quane	et	al.,	1998).	 	 In	addition	to	the	anti-inflammatory/analgesic	effect,	BZY	
has	local	anesthetic	effects	(Sato	and	Maehara,	1967;	Silvestrini	et	al.,	1966a,	1966b).	
Relatively	 little	 is	 known	 about	 the	 effects	 of	 BZY	 on	 the	 central	 nervous	 system.		
Symptoms	 such	 as	 hallucinations,	 dizziness,	 and	 anxiety	 have	 been	 reported	 as	 a	
consequence	of	unintended	systemic	ingestion	(Gómez-López	et	al.,	1999;	Ballesteros	et	al.,	
2009;	 Settimi	 et	 al.,	 2012;	 Acar	 et	 al.,	 2014).	 	 Most	 important,	 there	 is	 evidence	 of	
recreational	 use	 of	 BZY	 in	 various	 countries,	 including	 Brazil,	 Italy,	 Poland,	 and	 Turkey	
(Anand	et	 al.,	 2007;	Opaleye	et	 al.,	 2009,	 2011;	 Settimi	 et	 al.,	 2012;	Balaban	et	 al.,	 2013;	
Barwina	et	al.,	2014).		In	Brazil,	for	example,	BZY	has	been	abused	by	street	youth	since	at	
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least	 the	 early	 1990s,	 probably	 due	 to	 its	 low	price	 and	 ready	 availability	 (Opaleye	 et	 al.,	
2009).		In	the	following	two	decades	its	use	spread	to	Brazil	club	scene,	with	the	blossoming	
of	 theme	 rave	 parties	 (Benflogin®	 parties)	 and	 pop	 songs	 titled	 ‘Benzydamine’.	 	 Informal	
self-reports,	 hosted	 by	 internet	 drug	 forums	 and	 social	 networks,	 BZY	 and	 provide	
information	 about	 route	 of	 administration,	 dosage,	 and	 substance	 preparation	 from	
commercial	 preparations,	 as	 well	 as	 advice	 about	 other	 psychotropic	 substances	 to	 be	
assumed	with	BZY	to	enhance	its	pleasurable	effects	and	dampen	the	undesired	ones	(Souza	
et	al.,	2008).		Benzydamine	seems	to	be	particularly	popular	among	poly-drug	users	(Anand	
et	 al.,	 2007;	 Opaleye	 et	 al.,	 2009).	 	 We	 have	 recently	 reported	 BZY	 use	 among	 the	
outpatients	of	an	addiction	clinic	(Villa	Maraini	in	Rome,	Italy)	with	a	history	of	heroin	and	
cocaine	co-abuse	(Malavasi	et	al.,	2012).	
The	major	 aim	of	 the	 present	 study	was	 to	 assess	 the	 reinforcing	 effect	 of	 BZY	 in	
animal	model	of	drug	abuse.		In	particular,	we	investigated	the	ability	of	this	drug	to	sustain	
intravenous	self-administration	in	drug-naïve	rats	as	well	as	in	rats	that	had	been	previously	
trained	to	self-administer	cocaine	and	heroin,	to	mimic	the	drug	history	of	polydrug	abusers.		
The	second	aim	of	our	study	was	to	begin	characterizing	the	neurobiological	actions	
of	BZY,	as	virtually	nothing	is	known	in	this	regard.		We	investigated	the	electrophysiological	
effects	of	BZY	on	PLCx-NAcc	synapses,	a	circuitry	that	is	thought	to	play	an	important	role	in	
drug	 reward	 and	 drug	 seeking	 (Ikemoto	 and	 Panksepp,	 1999;	 Kalivas	 and	 Volkow,	 2005;	
Kalivas	 et	 al.,	 2009)	 and	 that	 has	 been	 shown	 to	 undergo	 neuroplastic	 changes	 following	
repeated	 drug	 administration	 (Van	 den	Oever	 et	 al.,	 2012;	Quintero,	 2013;	 Kalivas	 et	 al.,	
2009).		Interestingly,	other	drugs	of	abuse	with	hallucinogenic	properties	similar	to	those	of	
BZY,	 such	 as	 ketamine	 and	 PCP,	 have	 been	 shown	 to	 reduce	 glutamatergic	 transmission	
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(Anis	 et	 al.,	 1983).	 	 We	 also	 explored	 the	 possible	 involvement	 of	 CB1	 receptors	 in	 the	
electrophysiological	effects	of	BZY,	as	 the	chemical	 structure	of	BZY	 shares	 some	 features	
(e.g.,	 the	 benzoyl	 indole	 structure)	 with	 CB1	 synthetic	 agonists,	 which	 also	 have	
hallucinogenic	properties	(Forrester,	2012;	Harris	and	Brown,	2013).	
	
MATERIALS	AND	METHODS	
Experiment	1:	BZY	self-administration	
Animals	 and	 surgery:	 All	 the	 experimental	 procedures	 were	 carried	 out	 according	 the	
guidelines	 established	 by	 the	 European	 legislation	 (Directive	 2010/63/EU)	 and	 the	 Italian	
legislation	(L.D.	26/2014).	
A	 total	 of	 23	 male	 Sprague-Dawley	 rats	 (Harlan	 Laboratories)	 weighting	 250-300	 g	 upon	
arrival	 were	 used.	 	 The	 rats	 were	 housed	 in	 pairs	 in	 transparent	 plastic	 cages	 (40	 cm	 in	
length,	24.5	cm	in	width,	and	18	cm	in	height)	with	stainless	steel	grid	tops	and	flat	bottoms	
covered	 with	 ground	 corncob	 bedding,	 in	 a	 temperature	 (21±1	 °C)	 and	 humidity	 (70%)	
controlled	room	with	a	14-h	dark/10-h	light	cycle	(lights	off	at	0700	hours).		The	rats	were	
gently	 handled	 twice	 a	 week	 for	 two	 weeks	 before	 undergoing	 surgical	 catheterization,	
following	 procedures	 described	 previously	 in	 detail	 (Caprioli	 et	 al.,	 2008).	 	 On	 the	 day	 of	
surgery,	the	rats	received	an	intraperitoneal	 injection	of	2.33	mg	of	xylazine	hydrochloride	
(Rompun®,	 Bayer	 HealthCare)	 and	 0.56	 ml/kg	 of	 Zoletil	 100®	 (Virbac,	 Carros,	 France),	
containing	tiletamine	(50	mg/ml)	and	zolazepam	(50	mg/ml).		The	catheter	consisted	of	10.5	
cm	of	 silicone	 tubing	 (0.37-mm	 inner	diameter	and	0.94-mm	outer	diameter)	 sheathed	at	
3.4	 cm	 from	 its	 proximal	 end	 by	 a	 5-mm	 piece	 of	 heat-shrink	 tubing.	 	 The	 catheter	 was	
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inserted	 into	 the	 right	 jugular	 vein	 and	 secured	 to	 the	 surrounding	 soft	 tissues	 with	 silk	
thread.	 	 Catheter	 distal	 end	was	 externalized	 through	 a	 small	 incision	 at	 the	 nape	 of	 the	
neck	and	connected	to	an	L-shaped	22-gauge	cannula,	which	was	secured	to	rat’s	skull	using	
dental	 cement	 and	 stainless	 steel	 screws.	 	 After	 surgery,	 the	 rats	 were	 given	 15	 mg	 i.v.	
enrofloxacin	 (Baytril®,	 KVP	 Pharma	 +	 Veterinär	 Produkte	 Gmbh,	 Kiel,	 Germany).	 	 The	
catheters	were	flushed	daily	(1800	hours)	with	0.1	ml	of	sterile	saline	solution	containing	0.4	
mg	of	enrofloxacin	and	25	IU	heparin	(Marvecs	Services,	Agrate	Brianza,	Italy).		The	rats	had	
ad	 libitum	 access	 to	 food	 and	 water	 throughout	 the	 experiment,	 except	 during	 the	 self-
administration	sessions.	 	The	rats	were	allowed	to	recover	 from	the	surgery	 for	7-10	days	
and	 were	 then	 assigned	 to	 either	 the	 drug-naïve	 group	 (n=12)	 or	 the	 drug-experienced	
group	(n=11)	before	the	start	of	drug	self-administration.	
Apparatus:	 The	 apparatus	 (ESATEL	 S.r.l.;	 Rome,	 Italy)	 consisted	 of	 self-administration	
chambers	 (28.5-cm	 length,	 27-cm	 width,	 and	 32-cm	 height)	 made	 of	 transparent	 plastic	
(front	 and	 rear	 walls),	 aluminum	 (sidewalls	 and	 ceiling),	 and	 stainless	 steel	 (grid	 floor).		
Plastic	trays	covered	with	pinewood	shaving	were	placed	under	the	cage	floors.		Each	cage	
was	 equipped	 with	 a	 counterbalanced	 arm	 holding	 a	 liquid	 swivel	 and	 two	 retractable	
levers,	positioned	on	the	left-hand	wall	12.5	cm	apart	and	9	cm	above	the	floor.		Cue	lights	
consisting	 of	 either	 a	 set	 of	 triple	 (green,	 red,	 and	 yellow)	 LED	 lights	 (in	 the	 case	 of	
heroin/cocaine	self-administration)	or	a	single	white	light	(for	BZY	self-administration)	were	
positioned	 above	 each	 the	 two	 levers.	 	 The	 self-administration	 cages	were	 placed	within	
sound-	and	light-attenuating	cubicles.		Each	cage	was	connected	via	an	electronic	interface	
to	a	syringe	pump	(Razel	Scientific	Instruments,	St.	Albans,	VT,	USA)	and	to	a	programmable	
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logic	controller	(PLC;	Allen	Bradley,	Milwaukee,	WI,	USA).		Finally,	the	PLCs	were	connected	
to	PCs	running	control	software	developed	by	Aries	Sistemi	S.r.l.	(Rome,	Italy).	
Self-administration	 procedures	 in	 the	 drug-naïve	 group:	 The	 rats	 in	 the	 drug-naïve	 group	
underwent	fourteen	3-h	daily	sessions	of	BZY	self-administration.		Independent	groups	(n=4)	
self-administered	 one	 of	 three	 infusion	 doses	 of	 BZY	 (Sigma	Aldrich):	 250,	 500,	 and	 1000	
µg/kg	(dissolved	in	40	µl	of	sterile	saline	solution).		The	sessions	took	place	during	the	dark	
phase	between	0900	and	1700	hours.	 	During	the	session	both	 levers	were	extended,	but	
only	 one	 of	 them	 (counterbalanced	 across	 animals)	was	 ‘active’	whereas	 pressing	 on	 the	
other	 lever	 had	 no	 scheduled	 consequences	 except	 resetting	 the	 counter	 for	 the	 active	
lever.	 	The	number	of	consecutive	presses	(on	the	active	lever)	required	to	obtain	a	single	
drug	infusion	(fixed	ratio,	FR)	was	progressively	increased	during	training:	FR1	on	sessions	1-
7,	FR2	on	session	8,	FR3	on	session	9,	FR4	on	session	10,	and	finally	FR5	on	sessions	11-14.		
Once	the	appropriate	FR	had	been	reached,	a	drug	infusion	was	delivered	over	a	period	of	3	
s	and	at	the	same	time	both	levers	retracted	for	a	time-out	period	of	40	s.		A	white	cue	light	
above	 the	 active	 lever	was	on	 throughout	 the	 session	except	during	 the	 time-out	period.		
Rats	that	did	not	spontaneously	self-administer	at	least	one	infusion	within	the	first	5	min	of	
the	session	were	placed	with	their	forepaws	on	the	active	 lever,	so	as	to	trigger	a	priming	
infusion.	 	 Priming	 infusions	were	 administered	 again	 at	 times	 60	 and	 120	min	 to	 animals	
that	had	not	spontaneously	self-administered	at	least	one	infusion	during	time	periods	5-60	
and	60-120	min.		On	FR5	sessions	(days	11-14)	priming	infusions	were	given	only	to	rats	that	
failed	 to	 self-administer	 at	 least	 one	 infusion	 within	 the	 0-5	 min	 period.	 	 These	
experimenter-induced	 lever	presses	were	opportunely	 subtracted	 from	 the	 total.	 The	 rats	
were	allowed	to	self-administer	a	maximum	of	50	infusions	within	a	single	session.	
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Self-administration	 procedures	 in	 the	 drug-experienced	 group:	 The	 rats	 in	 the	 drug-
experienced	group	were	first	trained	to	self-administer	cocaine	and	heroin	on	alternate	days	
for	 12	 consecutive	 sessions	 (as	 previously	 described	 in	 detail	 by	 Caprioli	 et	 al.,	 2009	 and	
Montanari	et	al.,	2015).		Briefly,	during	this	phase	both	levers	were	paired	with	cocaine	and	
heroin	in	a	counterbalanced	manner.		At	the	start	of	each	session,	only	the	lever	associated	
with	the	drug	to	be	self-administered	on	that	session	was	extended,	and	the	appropriate	set	
of	cue	lights	was	turned	on.		Thus,	during	this	phase	pressing	on	both	levers	was	reinforced	
and	 there	was	 no	 ‘inactive’	 lever.	 	 After	 the	 completion	 of	 this	 procedure,	 the	 rats	were	
transferred	 to	 a	 different	 experimental	 room	 and	 given	 a	 5-day	 period	 of	 rest.	 	 The	 rats	
were	then	trained	to	self-administer	one	of	three	infusion	doses	of	BZY	(n=3-4),	as	described	
above	for	drug-naïve	rats.	 	Notice	that	 the	self-administration	procedures	 for	BZY	differed	
from	those	for	heroin	and	cocaine	in	three	major	ways:	i)	only	one	lever	(either	the	left	or	
the	 right	 lever,	 on	 alternate	 days)	 was	 extended	 during	 heroin	 and	 cocaine	 self-
administration	whereas	both	 levers	 (one	 ‘active’	 and	one	 ‘inactive’)	were	available	during	
BZY	 self-administration	 sessions;	 ii)	 the	 cue	 lights	 signaling	drug	availability	 consisted	of	 a	
set	 of	 triple	 (green,	 red,	 and	 yellow)	 LED	 lights	 in	 the	 case	 of	 heroin/cocaine	 self-
administration	 versus	 a	 single	 white	 light	 in	 the	 case	 of	 BZY	 self-administration;	 iii)	 two	
distinct	 testing	 rooms	 (and	 related	 contextual	 cues)	were	 used	 for	 heroin/cocaine	 versus	
BZY	self-administration.	
	
Experiment	2:	Slice	electrophysiology	
Animals:	Acute	brain	slices	were	obtained	from	18	drug-naïve	and	5	drug-experienced	male	
Sprague-Dawley	 rats	 of	 the	 same	 age	 of	 those	 used	 in	 the	 BZY	 self-administration	
10	
experiment	 (P60-90	 for	 drug-naïve	 rats	 and	 P80-100	 for	 drug-experienced	 rats).	 	 Drug-
experienced	animals	underwent	alternate	cocaine	and	heroin	self-administration	training	as	
detailed	in	the	previous	experiment	and	were	then	given	5-7	days	of	rest	in	their	home	cage	
before	 being	 anesthetized	 for	 brain	 slice	 collection.	 	 Notice	 that	 the	 rats	 used	 in	 the	
electrophysiology	experiments	did	not	receive	BZY	self-administration	training.	
Slice	collection:	Animals	were	deeply	anesthetized	with	halothane	(2-bromo-2-chloro-1,1,1-
trifluoroethane,	 Sigma-Aldrich)	 and	decapitated.	 	 The	brain	was	 rapidly	 removed	 and	300	
µm	thick,	parasagittal	slices	were	obtained	using	a	Leica	1200T	vibratome,	and	immersed	in	
a	cutting	solution	containing	(in	mM):	KCl	2.5,	NaH2PO4	1.25,	MgSO4	10,	CaCl2	0.5,	Choline	
120,	NaHCO3	26,	Glucose	10.		The	slices	were	then	incubated	in	artificial	cerebrospinal	fluid	
(aCSF)	in	a	holding	chamber	at	32°C	for	the	first	60	min	and	at	room	temperature	thereafter.	
Each	slice	was	transferred	to	a	recording	chamber	constantly	perfused	with	aCSF	(31-32°C,	
3-4	 ml/min)	 with	 the	 following	 composition	 (in	 mM):	 NaCl	 126,	 KCl	 1.25,	 NaH2PO4	 1.25,	
MgSO4	2,	CaCl2	2,	NaHCO3	26,	Glucose	10.		All	solutions	were	saturated	with	a	95%	O2	–	5%	
CO2	gas	mixture.	
Stimulation	and	recordings:	Field	excitatory	post	synaptic	potentials	(fEPSPs)	were	recorded	
by	 placing	 a	 glass	 recording	 electrode,	 filled	 with	 aCSF,	 in	 the	 Core	 of	 the	 Nucleus	
Accumbens	 (NAcc-Core).	 	 Prelimbic	 cortical	 afferents	 were	 stimulated	 by	 a	 25	 µs	 square	
wave	 current	 delivered	 at	 0.03	 Hz	 (a	 sweep	 every	 30	 s)	 through	 a	 bipolar	 stainless	 steel	
microelectrode	 placed	 at	 the	 border	 between	 PLCx	 and	 NAcc.	 	 The	 GABAAR	 antagonist	
picrotoxin	(100	µM)	was	added	to	the	perfusion	aCSF	due	to	presence	of	strong	GABAergic	
inhibition	 in	 the	 NAcc-Core.	 	 Signals	 were	 fed	 into	 a	 Multiclamp	 700b	 amplifier	 (Axon	
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Instruments),	filtered	at	1	kHz,	converted	by	a	Digidata	1322A	(Axon	Instruments),	acquired	
and	analyzed	using	Clampex	9.2	software.	
The	stimulus	intensity	that	evoked	a	fEPSP	of	50-60%	of	the	maximal	response	was	chosen	
to	 acquire	 the	 baseline	 response	 (15	 min)	 for	 all	 experiments.	 For	 short	 term	 plasticity	
experiments,	 a	 fEPSP	 of	 ∼50%	 of	 the	 maximum	 was	 obtained	 and	 two	 stimuli	 were	
delivered	with	a	120	ms	 inter-stimulus	 interval	 (ISI).	 	 Paired	Pulse	Ratio	was	calculated	as	
fEPSP2/fEPSP1	 (3	 sweeps	 average)	 right	 before	 and	 after	 BZY	 bath-perfusion.	 	 For	 all	
experiments,	BZY	was	added	at	 the	 final	 concentration	 to	 the	perfusion	aCSF.	 	 Preliminar	
experiments	showed	that	at	the	concentration	of	30	µM	BZY	was	effective	in	decreasing	the	
PLCx-NAcc	fEPSP	by	about	50%	after	30	min	of	exposure,	whereas	at	the	concentration	of	
100	µM	fEPSP	was	virtually	abolished.	 	Thus,	whereas	 in	 the	acute	perfusion	experiments	
the	exposure	 time	was	10	minutes	 (Fig.	 2),	 in	 the	 long	 term	plasticity	 study	 the	exposure	
time	to	100	µM	BZY	was	reduced	to	8	min	(Fig.	4).	
	
Data	analysis	and	statistics	
Data	were	analyzed	using	IBM	SPSS	20	statistical	software.		In	vivo	data	were	analyzed	using	
a	4-way	mixed	ANOVA	with	between-subject	factors	drug	experience	(drug	naïve	vs.	drug-
experienced)	and	dose	(3	levels)	and	with	repeated	measures	on	the	factors	lever	(active	vs.	
inactive)	 and	 session	 (14	 levels).	 	 Electrophysiological	 data	 were	 analyzed	 using	 ANOVAs	
with	 repeated	measures	 on	 the	 factor	 time.	 	 Data	 from	 PPR	 experiments	 were	 analyzed	
using	paired	samples	t-test.	
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RESULTS	
BZY	self-administration	
Figure	1	 illustrates	the	reinforcing	effects	of	BZY	on	 lever	pressing	as	a	function	of	session	
and	 drug	 experience.	 The	 acquisition	 of	 BZY	 self-administration	 was	 greatly	 facilitated	 in	
drug-experienced	rats	relative	to	drug	naïve	rats.		Notice	that	drug-experienced	rats	readily	
learned	to	discriminate	the	BZY-paired	lever	from	the	‘inactive’	lever	even	though	during	the	
cocaine/heroin	 training	 phase	 the	 rate	 of	 lever	 pressing	 on	 the	 two	 levers	 was	 virtually	
identical	(see	Supplementary	Information,	Fig.	S1).	 	A	4-way	ANOVA	indicated	a	significant	
main	 effect	 of	 lever	 [F1,17=30.008;	 p<0.001],	 session	 [F13,221=8.646;	 p=0.001],	 and	 drug	
experience	 [F1,21=7.721;	p=0.013].	 	There	were	also	 lever*session	 [F13,221=10.511;	p<0.001]	
and	lever*drug	experience	[F1,21=5.629;	p=0.03]	interactions.		Furthermore,	a	3-way	ANOVA	
of	the	number	of	 infusions	yielded	a	main	effect	of	session	[F13,221=2.672;	p=0.014]	and	of	
drug	experience	 [F1,17=14.564;	p=0.001],	as	well	as	 session*drug	experience	 [F13,221=3.183;	
p=0.004]	and	session*training	dose	[F26,221=2.119;	p=0.016]	interactions.	
	
Electrophysiological	recordings	
Bath	applications	of	BZY	at	concentrations	of	30	µM	for	30	min	or	100	mM	BZY	for	10	min	
decreased	PLCx-NAcc	fEPSP	amplitude	by	36.1±6.8%	(from	0.77±0.06	mV	to	0.51±0.09	mV,	
n=7)	 and	 64.8±5.7%	 (from	 0.75±0.07	 mV	 to	 0.27±0.05	 mV,	 n=7),	 respectively	 (Fig.	 2).		
Repeated	measures	ANOVA	run	separately	for	30	µM	and	100	mM	experimental	groups	on	
the	fEPSP	amplitude	from	the	time	period	15-45	showed	a	significant	effect	of	time	for	both	
the	30	µM	[F60,360=7.954;	p<0.001]	and	the	100	mM	concentration[F60,360=18.774;	p<0.001].	
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Furthermore,	 2-way	 repeated	measures	mixed	 ANOVA	 conducted	 on	 data	 from	 the	 time	
period	 15-25	 min	 yielded	 significant	 main	 effects	 of	 time	 [F20,240=9.763;	 p<0.001],	
concentration	 [F1,12=25.583;	p<0.001],	and	a	 time*concentration	 interaction	 [F20,240=5.253;	
p<0.001].	 	To	exclude	that	this	severe	depression	in	synaptic	transmission	could	be	due	to	
non-specific	toxic	effects	of	BZY,	pulses	of	higher	current	intensity	were	delivered	at	the	end	
of	each	experiment.		Under	these	experimental	conditions	the	depressed	fEPSPs	recovered	
to	the	baseline	amplitude	values	(data	not	shown).	
We	also	performed	short-term	plasticity	experiments	by	measuring	PPRs	to	assess	if	
BZY-mediated	 effects	 are	 due	 to	 alterations	 of	 neurotransmitter	 release	 probability.	 	 In	
control	 conditions,	 the	 second	 synaptic	 response	 (fEPSP2)	 was	 smaller	 than	 the	 first	
(fEPSP1)	(Fig.	2d),	a	phenomenon	termed	paired	pulse	depression.		Benzydamine	perfusion	
(30	 µM)	 further	 decreased	 PPR	 (from	 0.85±0.05	 baseline	 to	 0.59±0.03	 after	 30	 min	
perfusion;	 n=7;	 t6=4.978;	 p=0.003),	 suggesting	 a	 presynaptic	 mechanism	 of	 drug	 action	
(Creager	 et	 al.,	 1980;	 Wu	 and	 Saggau,	 1994).	 Due	 to	 the	 deep	 depression	 of	 the	 fEPSP	
induced	 by	 100	 µM	 BZY	 (Fig.	 2f),	 PPR	 data	 collected	 from	 these	 experiments	 were	 not	
included	in	the	analyses.	
The	fEPSP	depression	induced	by	BZY	was	significantly	enhanced	in	drug-experienced	
animals	 compared	 to	 naïve	 rats	 (Fig.	 3).	 	 Two-way	mixed	 ANOVA	 for	 repeated	measures	
unveiled	a	significant	main	effect	of	experience	[F1,21=9.237;	p=0.006]	and	experience*time	
interaction	[F59,1239=3.573;	p=0.01],	 indicating	sensitization	of	PLCx-NAcc	synapses	to	acute	
effects	 of	 BZY	 perfusion,	 in	 drug-experienced	 rats.	 Interestingly,	 baseline	 glutamatergic	
transmission	was	 lower	 in	 drug-experienced	 rats	 (Fig.	 3c),	 as	 indicated	 by	main	 effect	 of	
stimulus	intensity	[F4,84=44.224,	p<0.001]	and	experience	[F1,21=11.570;	p=0.009].	
14	
As	 shown	 in	Fig.	4a,	bath	application	of	100 µM	BZY	 for	8	min	 induced	 long	 term	
depression	of	fEPSP	amplitude	with	a	peak	of	-60.1±5.0%	at	min	25-35	(from	0.55±0.04	mV	
to	0.22±0.03	mV;	n=9;	t8=9.984;	p<0.001),	indicating	that	BZY	can	cause	long-term	changes	
of	 PLCx-NAcc	 synaptic	 connectivity.	 Longer	 time	 of	 BZY	 perfusion	 often	 resulted	 in	 the	
complete	suppression	of	the	fEPSP	(Fig.	2).	The	fEPSP	amplitude	did	not	fully	recover	during	
the	wash	out	 (from	0.55±0.04	mV	baseline	 to	0.36±0.03	mV	at	 time	70-80	min;	 t8=6.347;	
p<0.001)	 and	was	 still	 reduced	 (-33.4±4.5%)	 at	 the	end	of	 recordings.	 This	 stable	 LTD-like	
response	 was	 consistently	 reduced	 by	 the	 co-application	 of	 the	 CB1	 receptor	 antagonist	
AM251	(F1,19=18.635;	p<0.001;	Fig.	4a).		In	the	presence	of	AM251	2	µM,	BZY-induced	fEPSP	
depression	was	smaller	than	in	the	BZY	group	both	at	the	depression	peak	(-35.8±5.7%	vs.	-
60.1±5.0%;	 n=12;	 t19=3.071;	 p=0.006)	 and	 at	 the	 end	 of	 recordings	 (-13.9±3.5%	 vs.	 -
33.4±4.5%;	t19=3.420;	p=0.003).	 	Repeated	measures	mixed	ANOVA	on	PPR	data	showed	a	
significant	time	point*treatment	interaction	[F2,40=5.548;	p=0.007].		The	reduction	of	PPR	by	
BZY	 (from	0.85±0.03	baseline	 to	 0.73±0.04	 in	 the	BZY	 group;	 t8=2.664;	 p=0.012)	was	 fully	
counteracted	 by	 AM251	 co-perfusion	 (from	 0.86±0.05	 baseline	 to	 0.93±0.07	 in	 the	
BZY+AM251	group;	t11=1.577;	p=0.143;	Fig	4b).		AM251	did	not	affect	PPR	per	se	(0.93±0.06,	
p=0.175	 vs	 baseline	 PPR,	 data	 not	 shown).	 	 Consistent	 with	 these	 results	 during	 the	
perfusion	of	the	CB1	agonist	WIN55,212-2	(1	µM)	the	amount	of	 fEPSP	depression	by	BZY	
was	smaller	by	62.8±4.7%	than	BZY	applied	alone	(n=10,	Fig	c),	thus	suggesting	that	BZY	and	
WIN55,212-2	share	a	common	pathway.		Taken	together	these	data	indicate	that	the	effects	
of	BZY	on	glutamatergic	neurotransmission	are	likely	mediated	by	cannabinoid	mechanisms.	
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DISCUSSION	
We	report	here	three	major	novel	findings.	 	First,	we	found	that	BZY,	a	non-steroidal	anti-
inflammatory	 drug,	 is	 self-administered	 intravenously	 by	 rats	 and	 that	 the	 reinforcing	
effects	of	BZY	are	greatly	enhanced	by	a	history	of	heroin	and	cocaine	self-administration.		
Second,	 we	 found	 that	 BZY	 induces	 LTD-like	 plasticity	 at	 PLCx-NAcc	 synapses.	 Third,	 we	
found	 that	 this	 latter	 effect	 was	 significantly	 reduced	 by	 the	 CB1	 receptor	 antagonist	
AM251,	suggesting	a	cannabinoidergic	mechanism	of	action.	
Benzydamine	 abuse	 is	 well	 documented	 in	 Brazil	 (Opaleye	 et	 al.,	 2009,	 2011)	 and	 other	
countries,	 including	 Italy	 (Malavasi	et	al.,	2012;	Settimi	et	al.,	2012),	Poland	 (Anand	et	al.,	
2007),	and	Turkey	(Balaban	et	al.,	2013).		The	finding	that	BZY	is	reinforcing	in	the	rat	sheds	
a	 light	 on	 two	 aspects	 of	 BZY	 abuse	 in	 humans.	 	 The	 first	 aspect	 concerns	 its	 addictive	
potential.	 	 There	 is	 little	 information	 on	 the	 subjective	 effects	 of	 BZY	 in	 the	 scientific	
literature,	 except	 for	 its	 hallucinogenic	 effects	 (Opaleye	 et	 al.,	 2009).	 	 Yet,	 hallucinogenic	
substances	 such	 as	 LSD,	 mescaline,	 and	 DOM,	 have	 relatively	 little	 addictive	 potential	 in	
humans	 (Nutt	 et	 al.,	 2007)	 and	 there	 is	 little	 or	 no	 evidence	 of	 self-administration	 of	 in	
rodents	(Deneau	et	al.,	1969;	Yanagita,	1986).		However,	informal	subjective	reports	posted	
in	 drug	 forums,	 indicate	 that	 BZY	 has	 both	 stimulant	 and	 hallucinogenic	 properties.		
Substances	 with	 mixed	 hallucinogenic	 and	 psychostimulant	 effects,	 such	 as	 MDMA	 or	
ketamine,	 have	 greater	 abuse	 potential	 than	 purely	 hallucinogenic	 drugs	 and	 are	 self-
administered	 by	 monkeys	 (Lamb	 and	 Griffiths,	 1987;	 Fantegrossi	 et	 al.,	 2002)	 and	 rats	
(Ratzenboeck	et	 al.,	 2001;	 Schenk	et	al.,	 2003;	De	 Luca	et	 al.,	 2011;	De	 Luca	and	Badiani,	
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2012).	 	 In	summary,	the	reinforcing	effects	of	BZY	described	here	 in	the	rat	are	consistent	
with	the	stimulant	and	hallucinogenic	effects	reported	in	drug	forums.	
The	 second	 important	 aspect	 of	 BZY	 abuse	 is	 that	most	 cases	 concern	 individuals	with	 a	
history	 of	 drug	 addiction	 and	 polydrug	 use	 (Anand	 et	 al.,	 2007;	 Opaleye	 et	 al.,	 2009;	
Malavasi	 et	 al.,	 2012),	 suggesting	 that	 the	 reinforcing	 effects	 of	 BZY	 are	 facilitated	 by	
previous	drug	exposure.		Indeed,	in	the	present	study	we	found	that	although	BZY	acted	as	a	
positive	reinforcer	 in	both	naïve	rats	and	 in	rats	with	a	history	of	cocaine	and	heroin	self-
administration,	 the	 latters	acquired	BZY	self-administration	at	a	very	 low	unit	dose,	which	
was	not	effective	in	naïve	rats.	
The	mechanism	underlying	the	reinforcing	effects	of	BZY	is	unknown.		Actually,	to	the	best	
of	our	knowledge,	this	is	the	first	study	reporting	on	the	neurobiological	effects	of	BZY.		We	
have	 shown	 that	 BZY	 can	 produce	 short-	 and	 long-term	 changes	 in	 excitatory	 synaptic	
transmission	 in	 the	 PLCx-NAcc	 circuitry.	 In	 particular,	 acute	 BZY	 reduced	 PLCx-NAcc	
glutamatergic	 transmission	via	a	presynaptic	mechanism.	 	The	depressive	effect	of	BZY	on	
glutamatergic	 transmission	 was	 greater,	 similar	 to	 its	 reinforcing	 effect,	 in	 rats	 that	 had	
previously	self-administered	cocaine	and	heroin	than	in	naïve	rats.		This	phenomenon	might	
be	related	to	differences	 in	baseline	PLCx-NAcc	glutamatergic	transmission	as	 indicated	by	
the	 input-output	 curves	 for	 the	 two	 groups	 (see	 Fig.	 3)	 or	 to	 alterations	 of	 cannabinoid	
signalling	 between	 drug-experienced	 and	 drug-naïve	 animals	 (Rivera	 et	 al.,	 2013).		
Interestingly,	 previous	 studies	 have	 shown	 that	 cocaine	 and	 d-amphetamine	 can	 depress	
excitatory	neurotransmission	at	PLCx-NAcc	synapses	via	dopamine	DA1	receptors	(Nicola	et	
al,	 1996).	 	 However,	 BZY-induced	 LTD	 does	 not	 appear	 to	 depend	 on	 dopaminergic	
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mechanisms	 since	 it	was	 not	 affected	by	 the	 selective	D1	 antagonist	 SCH23390	 (data	 not	
shown).			
In	contrast,	the	BZY-induced	LTD	of	glutamatergic	transmission	seems	to	depend	at	least	in	
part	on	 the	presence	of	CB1	 receptors	on	glutamatergic	presynaptic	 terminals.	 	The	CB1R	
antagonist	AM251	reduced	in	fact	BZY-induced	LTD	as	well	as	BZY-induced	changes	in	PPR.		
Interestingly	 amphetamine	 has	 been	 found	 to	 induce	 CB1-dependent	 LTD	 in	 the	 rat	
amygdala	(Huang	et	al.,	2003).	 	The	mechanism	by	which	BZY	interacts	with	CB1	receptors	
remains	unclear.		Benzydamine	might	act	as	a	direct	agonist	at	CB1	receptors.		Activation	of	
CB1	receptors	by	WIN	55,212,2	has	been	shown	in	fact	to	induce	persistent	and	long	lasting	
fEPSP	 LTD	 in	 the	 NAcc	 (Robbe	 et	 al.,	 2002).	 	 Consistent	 with	 this	 hypothesis,	 occlusion	
experiments	the	CB1	receptor	agonist	WIN	corroborated	that	the	partial	inhibition	of	BZY	by	
AM251	 was	 due	 to	 the	 involvement	 of	 CB1	 receptors	 (Fig.	 5).	 	 Alternatively,	 BZY	 might	
influence	 endocannabinoid	 synthesis	 and	 release	 (Löffler	 et	 al.,	 1987),	 which	 in	 turn	
regulates	glutamatergic	transmission	(Domenici	et	al.,	2006).		Of	course,	given	that	AM251	
dampened	but	not	abolished	BZY-induced	LTD	it	is	not	possible	to	exclude	the	contribution	
of	other	neurotransmitter	systems.	
The	critical	role	of	CB1R	in	modulating	BZY-induced	synaptic	plasticity	provides	a	potential	
mechanism	 for	 the	 abuse	 potential	 of	 BZY.	 	 Interestingly,	 the	 chemical	 structure	 of	 BZY	
shares	 some	 features	 (like	 the	 presence	 of	 a	 benzoyl	 indole)	 with	 several	 CB1	 synthetic	
agonists	(i.e.	the	JWH	series	compounds),	which	have	been	shown	to	possess	hallucinogenic	
proprieties	 (Forrester,	 2012;	 Harris	 and	 Brown,	 2013).	 	 Future	 self-administration	 studies	
utilizing	 CB1	 antagonists	 will	 be	 necessary	 to	 fully	 elucidate	 the	 degree	 to	 which	 CB1	
receptors	are	involved	in	the	reinforcing	effects	of	BZY.	
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In	conclusion,	we	provide	here	the	first	empirical	evidence	of	the	reinforcing	effects	of	BZY	
and	of	its	ability	to	produce	short-	and	long-term	changes	in	glutamatergic	transmission	in	
PLCx-NAcc	 synapses	 (a	 circuitry	 implicated	 in	 drug	 reward),	 possibly	 mediated	 by	 a	
cannabinoidergic	 mechanism	 of	 action.	 	 Further	 research	 is	 needed	 in	 order	 to	 better	
characterize	 these	 neurophysiological	 effects	 of	 BZY.	 	 Our	 findings	 also	 suggest	 that	
individuals	with	a	history	of	substance	abuse	might	be	more	prone	to	develop	BZY	abuse	not	
only	 as	 a	 consequence	 of	 a	 general	 predisposition	 to	 experiment	 with	 psychoactive	
substances,	 but	 also	 because	 of	 a	 specific	 pharmacological	 cross-sensitization	 to	 its	
reinforcing	effects.		This	could	be	of	particular	relevance	for	the	management	of	detention	
facilities	 or	 rehabilitation	 clinics,	 considering	 that	 an	 addict	might	 consume	BZY	 (o	 similar	
substances)	 as	 a	 substitute	 drug	 without	 even	 being	 noticed	 by	 supervisors,	 thus	
unpredictably	compromising	health	conditions	along	with	therapy	efficacy.			 	
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Figure	Legends	
Figure	1.		Lever	pressing	behavior	during	3-h	daily	sessions	of	BZY	self-administration.		FR	is	
progressively	increased	throughout	training.	 	Drug	experienced	animals	readily	acquire	the	
self-administration	 behavior	 for	 all	 dosages,	 while	 naïve	 animals	 do	 so	 only	 for	 higher	
dosages.		Values	are	displayed	as	means	±	SEM.	
Figure	2.	 	Effect	of	BZY	perfusion	on	PLCx-NAcc	glutamatergic	 fEPSP.	 	a)	Mean	normalized	
fEPSP	amplitude	during	perfusion	of	BZY	30	µM	(n=7	slices/3	animals,	30	min)	and	100	µM	
(n=7	 slices/3	 animals,	 10	 min).	 	 b)	 Schematic	 of	 electrode	 placement	 with	 mediolateral	
coordinates	from	bregma.		c-e)	Representative	time-course	of	an	experiment	for	BZY	30	µM	
and	100	µM	perfusion	with	sample	traces	from	different	time	points.	Traces	were	obtained	
by	averaging	3-4	 sweeps.	 	d-f)	Paired	Pulse	Ratio	 (PPR)	 values	measured	 right	before	and	
right	after	the	30	minutes	perfusion	of	BZY	30	µM	or	the	10	minutes	perfusion	of	BZY	100	
µM.	 	 BZY	 induced	 a	 significant	 reduction	 in	 PPR	 at	 PLCx-NAcc	 synapses.	 	 Representative	
traces	are	displayed	above	the	histograms.		*	indicates	significantly	different	(p<0.05)	from	
preBZY	PPR.		Values	are	displayed	as	means	±	SEM.	
Figure	 3.	 	 fEPSP	depression	 induced	by	 30	µM	BZY	 is	 enhanced	 in	 drug	 experienced	 rats’	
brain	 slices.	 	 a)	 BZY-induced	 fEPSP	 depression	 in	 brain	 slices	 from	 naïve	 (n=13	 slices/7	
animals)	and	drug	experienced	rats	(n=10/5).		b)	Representative	traces	from	experiments	on	
brain	slices	collected	from	naïve	or	drug	experienced	rats.		Traces	were	obtained	averaging	
3-4	sweeps	at	baseline	and	the	end	of	the	30	min	BZY	perfusion.	 	c)	 Input/output	curve	in	
baseline	PLCx-NAcc	glutamatergic	transmission	in	naïve	versus	drug	experienced	animals.		d)	
Paired	 Pulse	 Ratio	 (PPR)	 values	 measured	 right	 before	 and	 right	 after	 the	 30	 minutes	
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perfusion	of	BZY	30	µM.	*	indicates	significant	differences	(p<0.05)	between	drug	naïve	and	
drug	experienced	rats.			Values	are	displayed	as	means	±	SEM.	
Figure	 4.	 	 BZY	 induces	 stable	 LTD	 at	 the	 PLCx-NAcc	 synapses	 that	 is	 partially	 related	 to	
cannabinoid	 signaling.	 	 For	 the	 sake	 of	 clarity,	 the	 effects	 of	 AM251	 and	WIN55,212	 are	
shown	separately	even	thought	the	controls	are	the	same.		a)	Normalized	fEPSP	amplitude	
in	response	to	100	µM	BZY	perfusion	for	8	min	(n=10	slices/6	animals).		AM251	(2	µM)	co-
perfusion	significantly	reduces	the	BZY-induced	LTD	(n=12	slices/8	animals).	b)	Paired	Pulse	
Ratio	 values	measured	 at	 different	 time	 points	 (as	 depicted	 by	 numbers)	 show	 that	 BZY-
mediated	alteration	of	glutamate	release	was	significantly	 inhibited	by	the	CB1	antagonist	
AM251.	 	 c)	WIN55,212	 (1	 µM)	 reduces	 fEPSP	 amplitude	 by	 14.5±3.2%.	 In	 the	 continuous	
presence	of	the	CB1	agonist,	fEPSP	depression	by	100	µM	BZY	is	by	14±4.7%	(n=10	slices	/6	
animals).	Arrows	indicate	onset	and	offset	of	BZY	perfusion.		d)	Co-perfusion	of	WIN55,212	
masks	BZY	effects	on	Paired	Pulse	Ratio.		*	indicates	significantly	different	(p<0.05)	from	BZY	
group,	same	time	point	(2);	#	indicates	significantly	different	(p<0.05)	from	BZY	baseline	(1).		
Values	are	displayed	as	means	±	SEM.	
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